Abbott to Develop and Commercialise Biotest’s BT-061 for Autoimmune Diseases

By Heather Cartwright

Pharma Deals Review: Vol 2011 Issue 6 (Table of Contents)

Published: 27 Jun-2011

DOI: 10.3833/pdr.v2011.i6.1486     ISSN: 1756-7874

Section: Licensing



Abbott has licensed exclusive global rights to Biotest’s BT-061, a novel humanised anti-CD4 antibody in Phase II development for rheumatoid arthritis and psoriasis that could become a successor to Humira® (adalimumab)...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details